---
title: "Kiora Pharmaceuticals | 8-K: FY2025 Q2 EPS: USD -0.54"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252215607.md"
published_at: "2025-08-08T11:15:38.000Z"
---

# Kiora Pharmaceuticals | 8-K: FY2025 Q2 EPS: USD -0.54

EPS: As of FY2025 Q2, the actual value is USD -0.54.

EBIT: As of FY2025 Q2, the actual value is USD -2.265 M.

### Financial Highlights

-   **Net Loss**: Kiora Pharmaceuticals reported a net loss of $2.2 million for the second quarter of 2025, consistent with the net loss of $2.2 million in the second quarter of 2024.
    
-   **Research and Development (R&D) Expenses**: R&D expenses for the second quarter of 2025 were $2.6 million, before recognizing $1.7 million in reimbursable expenses from Théa. This is an increase from $2.0 million in the second quarter of 2024, with $1.1 million in offsetting reimbursable expenses from Théa.
    
-   **General and Administrative (G&A) Expenses**: G&A expenses were $1.4 million for the second quarter of 2025, down from $1.5 million in the second quarter of 2024.
    
-   **Cash and Cash Equivalents**: The company ended the quarter with $20.7 million in cash, cash equivalents, and short-term investments.
    
-   **Collaboration Receivables**: Kiora recorded $1.2 million in collaboration receivables from Théa for reimbursable R&D expenses and $1.25 million in collaboration receivables from Senju related to the option fee.
    
-   **Deferred Revenue**: The company recorded deferred revenue of $1.25 million related to a non-refundable option fee from Senju.
    

### Outlook / Guidance

Kiora Pharmaceuticals anticipates maintaining its cash runway into late 2027, which extends beyond the anticipated data readouts for the KLARITY and ABACUS-2 trials. The company is actively recruiting for its Phase 2 clinical trials, with strategic partnerships expected to enhance global commercialization efforts. The potential deal with Senju could be valued at up to $110 million plus royalties, contingent on the exercise of the option agreement.

### Related Stocks

- [KPRX.US - Kiora Pharmaceuticals](https://longbridge.com/en/quote/KPRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Kiora Pharmaceuticals Granted U.S. Patent for Novel KIO-104 Anti-Inflammatory Formulations | Kiora Pharmaceuticals Inc. has been granted a new U.S. patent for novel formulations of its KIO-104 anti-inflammatory co | [Link](https://longbridge.com/en/news/268071890.md) |
| Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating | Analyst Michael Okunewitch of Maxim Group has maintained a Buy rating on Kiora Pharmaceuticals with a price target of $1 | [Link](https://longbridge.com/en/news/265448589.md) |
| Kiora Pharmaceuticals posts third quarter results and reports ongoing Phase 2 trials for retinal diseases | Kiora Pharmaceuticals Inc. reported its third quarter 2025 results, ending with $19.4 million in cash and equivalents. T | [Link](https://longbridge.com/en/news/264841802.md) |
| Eyes On Kiora - ABACUS-2 And KLARITY Data Readouts Due In 2027 | Kiora Pharmaceuticals (KPRX) is developing two drug candidates for retinal diseases: KIO-301 for inherited retinal disea | [Link](https://longbridge.com/en/news/264192714.md) |
| Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 | Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025. | [Link](https://longbridge.com/en/news/261237964.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
